NCT05896839 RECRUITING Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
National Cancer Institute (NCI)
NCT05947500 ACTIVE NOT RECRUITING Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
National Cancer Institute (NCI)
NCT02978625 ACTIVE NOT RECRUITING Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
NCT07576725 NOT YET RECRUITING Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
NCT06814496 RECRUITING Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT07115043 RECRUITING A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
NCT04349436 ACTIVE NOT RECRUITING Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Replimune, Inc.
NCT07472322 NOT YET RECRUITING ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1
University of Wisconsin, Madison
NCT05583708 RECRUITING Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Weill Medical College of Cornell University
NCT05969860 RECRUITING At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT07387198 NOT YET RECRUITING Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT04291885 ACTIVE NOT RECRUITING Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Melanoma and Skin Cancer Trials Limited
NCT04869137 ACTIVE NOT RECRUITING Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04792073 ACTIVE NOT RECRUITING Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT04261855 ACTIVE NOT RECRUITING Targeted Therapy and Avelumab in Merkel Cell Carcinoma
Melanoma and Skin Cancer Trials Limited
NCT05269381 RECRUITING Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Mayo Clinic
NCT03071406 ACTIVE NOT RECRUITING Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT03074513 ACTIVE NOT RECRUITING Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
NCT06223659 RECRUITING EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Ohio State University Comprehensive Cancer Center
NCT06047379 RECRUITING Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
NCT05496036 RECRUITING Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Abramson Cancer Center at Penn Medicine
NCT06151236 RECRUITING Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Melanoma Institute Australia
NCT07288073 RECRUITING TIL Therapy in cSCC and MCC
Karam Khaddour, MD, MS
NCT06056895 ACTIVE NOT RECRUITING Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
University of Washington
NCT03228667 ACTIVE NOT RECRUITING QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
NCT05594290 ACTIVE NOT RECRUITING Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery
Gruppo Oncologico del Nord-Ovest
NCT05100095 RECRUITING Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
M.D. Anderson Cancer Center
NCT07285044 RECRUITING The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT05120271 ACTIVE NOT RECRUITING BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
Sotio Biotech Inc.
NCT02479698 RECRUITING Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
NCT05864144 ACTIVE NOT RECRUITING A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
NCT03935893 RECRUITING Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT05086692 RECRUITING A Beta-only IL-2 ImmunoTherapY Study
Medicenna Therapeutics, Inc.
NCT05013099 ACTIVE NOT RECRUITING Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
ImaginAb, Inc.
NCT06086288 NOT YET RECRUITING Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT03304639 COMPLETED Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
National Cancer Institute (NCI)
NCT04902040 TERMINATED Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
NCT06939036 TERMINATED Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Ariceum Therapeutics GmbH
NCT04260802 TERMINATED A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
NCT04916002 TERMINATED A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
NCT04725331 TERMINATED A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
NCT03901573 TERMINATED High-Risk Skin Cancers With Atezolizumab Plus NT-I7
NeoImmuneTech
NCT03599713 COMPLETED A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Incyte Corporation
NCT02196961 COMPLETED Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation
Prof. Dr. med. Dirk Schadendorf
NCT03167164 WITHDRAWN QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
ImmunityBio, Inc.
NCT02819843 COMPLETED A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT03853317 TERMINATED QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
ImmunityBio, Inc.
NCT04393753 COMPLETED Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1
4SC AG
NCT02465957 TERMINATED QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
ImmunityBio, Inc.
NCT02267603 COMPLETED Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
National Cancer Institute (NCI)
NCT01440816 COMPLETED IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
OncoSec Medical Incorporated
NCT02036476 TERMINATED Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
NCT04590781 TERMINATED Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
Xencor, Inc.
NCT03435640 TERMINATED REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Nektar Therapeutics
NCT02643303 COMPLETED A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
NCT01013779 COMPLETED Merkel Positron Emission Tomography (PET) Protocol
Trans Tasman Radiation Oncology Group
NCT03684785 TERMINATED Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Exicure, Inc.
NCT02584829 TERMINATED Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Fred Hutchinson Cancer Center
NCT04874831 WITHDRAWN Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
4SC AG
NCT03988647 TERMINATED Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
Stanford University
NCT02514824 COMPLETED MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
NCT01913691 WITHDRAWN Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
National Cancer Institute (NCI)
NCT02054884 TERMINATED F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Philogen S.p.A.
NCT01758458 TERMINATED Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Fred Hutchinson Cancer Center
